Evinature, a pioneering healthcare company, showcased its revolutionary nutraceutical, CurQD®, at the Crohn's & Colitis Congress held at Bellagio, Las Vegas, from the 25th to the 27th of January 2024. This annual event serves as a nexus for healthcare and medical professionals worldwide, fostering collaboration and sharing insights on the latest developments in the treatment of inflammatory bowel disease (IBD).
Evinature made headlines last year by presenting the groundbreaking results from the CurQD® randomized controlled trial for the first time in the United States. This marked a significant milestone, solidifying CurQD® as a promising treatment for combating IBD. This year, Evinature continued to build on its success at the Crohn's & Colitis Congress, where the company was abuzz with activity as healthcare professionals, researchers, and industry experts sought more information on CurQD®.
First US-Based CurQD® Study on Pediatric Cases
The congress saw a remarkable development as a separate trial on CurQD® was presented by other researchers. Dr. Mallory Chavannes led the first U.S.-based study focusing on pediatric cases with ulcerative colitis (UC) at the renowned Los Angeles Children's Hospital.
In this case series involving eight children, the clinical and radiological responses to the novel nutraceutical agent CurQD® were investigated.
"We presented our local experience using CurQD® as an adjunct treatment to standard therapy in our pediatric patient population with IBD," Dr. Mallory Chavannes states. "We were impressed to note that most patients experienced not only symptomatic improvement after starting CurQD®, but also had objective findings of improvement, such as biochemical markers and/or intestinal ultrasound. From our case series of 8 patients, 7/8 had symptomatic improvement by clinical scores, and all 5 patients who received pre and post-treatment intestinal ultrasound showed some level of improvement either by Doppler signaling alone or both Doppler and decreased bowel wall thickness."
Furthermore, the study suggests that CurQD® shows promise in treating IBD and calls for larger randomized controlled trials to assess its safety and efficacy, particularly in children. The use of intestinal ultrasound is highlighted as a practical tool for evaluating therapeutic response in a clinical setting.
Within just four weeks of treatment with CurQD®, these young patients demonstrated significant improvement, as evidenced by follow-up intestinal ultrasound scans.
Evinature Expands with Multiple Collaborations
What makes this development even more noteworthy is the swift acceptance and collaboration CurQD® has garnered within the medical community. Driven by the urgency to find effective solutions for IBD, over thirty U.S. medical centers have now partnered with Evinature. Leading doctors are actively referring patients to explore the benefits of CurQD®, and the company has secured substantial distribution deals across Europe, particularly in Spain.
Evinature has also made significant strides in making CurQD an accessible healthcare solution through its online platform, treating nearly 10,000 IBD patients, the majority in the United States. This success is a testament to the transformative impact that Evinature has had on IBD care within a remarkably short timeframe.
The Evinature team had the opportunity to meet with both new and long-term collaborators, as well as representatives from CCF Ventures, an organization that promotes patient education, R&D, and community support for IBD patients. Together, they discussed future avenues for spreading vital information that can benefit the Crohn's and Colitis community.
Nir Salomon, Co-Founder and Head of Research and Development at Evinature is thrilled by the rapid adoption of CurQD® within the medical community and among patients. He remarked, "It's incredible to see how fast this novel treatment was embraced by the medical community and patients within one year since we introduced CurQD®. These conferences have a huge impact, and we're extremely honored to take part and be presented."
Conclusion
The Crohn's & Colitis Congress serves as a vital platform for disseminating groundbreaking research, fostering collaboration, and catalyzing advancements in the field of IBD. Evinature's presence at this prestigious event not only highlights the success of CurQD® but also underscores the collective dedication of healthcare professionals in the relentless pursuit of effective treatments for IBD.
* This is a contributed article and this content does not necessarily represent the views of sciencetimes.com
